Human Leukocyte Antigen Haplotypes in the Genetic Control of Immune Response to Measles-Mumps-Rubella Vaccine
To elucidate the contribution of human leukocyte antigen (HLA) haplotypes and their genotypic combinations to immune status after measles-mumps-rubella (MMR) vaccination, 346 children 12–18 years of age were studied. The class I A*29-Cw*16-B*44 haplotype was associated with lower levels of immunoglo...
Saved in:
Published in | The Journal of infectious diseases Vol. 193; no. 5; pp. 655 - 663 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Chicago, IL
The University of Chicago Press
01.03.2006
University of Chicago Press Oxford University Press |
Subjects | |
Online Access | Get full text |
ISSN | 0022-1899 1537-6613 |
DOI | 10.1086/500144 |
Cover
Loading…
Abstract | To elucidate the contribution of human leukocyte antigen (HLA) haplotypes and their genotypic combinations to immune status after measles-mumps-rubella (MMR) vaccination, 346 children 12–18 years of age were studied. The class I A*29-Cw*16-B*44 haplotype was associated with lower levels of immunoglobulin G (IgG) antibody to both measles (P=.08) and mumps (P=.03) viral antigens. The A*26-Cw*12-B*38 haplotype was associated with higher cellular immune responses to measles (P=.02) and mumps (P=.01) vaccine viruses. Subjects with the class II DRB1*03-DQB1*02-DPB1*04 haplotype had higher lymphoproliferative responses to measles virus (P=.01) and mumps virus (P=.006). The DRB1*15/16-DQB1*06-DPB1*03 haplotype was associated with high levels of IgG antibody to measles virus (P=.09) but low levels of IgG antibody to rubella virus (P=.02), whereas DRB1*04-DQB1*03-DPB1*03 was associated with high lymphoproliferative responses to both measles (P=.01) and rubella (P=.002) vaccine viruses. A*26-Cw*12-B*38 was associated with both mumps virus–specific humoral (P=.007) and cell-mediated (P=.01) immune responses after 2 doses of MMR vaccine. Haplotype DRB1*04-DQB1*03-DPB1*03 was associated with both lower rubella virus IgG antibody levels (P=.02) and higher rubella virus–specific lymphoproliferation (P=.002). Better characterization of such HLA profiles could inform and improve the design of novel epitope-rich vaccines and help to predict protective immune responses at the individual and population level |
---|---|
AbstractList | To elucidate the contribution of human leukocyte antigen (HLA) haplotypes and their genotypic combinations to immune status after measles-mumps-rubella (MMR) vaccination, 346 children 12-18 years of age were studied. The class I A*29-Cw*16-B*44 haplotype was associated with lower levels of immunoglobulin G (IgG) antibody to both measles (P=.08) and mumps (P=.03) viral antigens. The A*26-Cw*12-B*38 haplotype was associated with higher cellular immune responses to measles (P=.02) and mumps (P=.01) vaccine viruses. Subjects with the class II DRB1*03-DQB1*02-DPB1*04 haplotype had higher lymphoproliferative responses to measles virus (P=.01) and mumps virus (P=.006). The DRB1*15/16-DQB1*06-DPB1*03 haplotype was associated with high levels of IgG antibody to measles virus (P=.09) but low levels of IgG antibody to rubella virus (P=.02), whereas DRB1*04-DQB1*03-DPB1*03 was associated with high lymphoproliferative responses to both measles (P=.01) and rubella (P=.002) vaccine viruses. A*26-Cw*12-B*38 was associated with both mumps virus-specific humoral (P=.007) and cell-mediated (P=.01) immune responses after 2 doses of MMR vaccine. Haplotype DRB1*04-DQB1*03-DPB1*03 was associated with both lower rubella virus IgG antibody levels (P=.02) and higher rubella virus-specific lymphoproliferation (P=.002). Better characterization of such HLA profiles could inform and improve the design of novel epitope-rich vaccines and help to predict protective immune responses at the individual and population level. To elucidate the contribution of human leukocyte antigen (HLA) haplotypes and their genotypic combinations to immune status after measles-mumps-rubella (MMR) vaccination, 346 children 12-18 years of age were studied. The class I A*29-Cw*16-B*44 haplotype was associated with lower levels of immunoglobulin G (IgG) antibody to both measles (P=.08) and mumps (P=.03) viral antigens. The A*26-Cw*12-B*38 haplotype was associated with higher cellular immune responses to measles (P=.02) and mumps (P=.01) vaccine viruses. Subjects with the class II DRB1*03-DQB1*02-DPB1*04 haplotype had higher lymphoproliferative responses to measles virus (P=.01) and mumps virus (P=.006). The DRB1*15/16-DQB1*06-DPB1*03 haplotype was associated with high levels of IgG antibody to measles virus (P=.09) but low levels of IgG antibody to rubella virus (P=.02), whereas DRB1*04-DQB1*03-DPB1*03 was associated with high lymphoproliferative responses to both measles (P=.01) and rubella (P=.002) vaccine viruses. A*26-Cw*12-B*38 was associated with both mumps virus-specific humoral (P=.007) and cell-mediated (P=.01) immune responses after 2 doses of MMR vaccine. Haplotype DRB1*04-DQB1*03-DPB1*03 was associated with both lower rubella virus IgG antibody levels (P=.02) and higher rubella virus-specific lymphoproliferation (P=.002). Better characterization of such HLA profiles could inform and improve the design of novel epitope-rich vaccines and help to predict protective immune responses at the individual and population level.To elucidate the contribution of human leukocyte antigen (HLA) haplotypes and their genotypic combinations to immune status after measles-mumps-rubella (MMR) vaccination, 346 children 12-18 years of age were studied. The class I A*29-Cw*16-B*44 haplotype was associated with lower levels of immunoglobulin G (IgG) antibody to both measles (P=.08) and mumps (P=.03) viral antigens. The A*26-Cw*12-B*38 haplotype was associated with higher cellular immune responses to measles (P=.02) and mumps (P=.01) vaccine viruses. Subjects with the class II DRB1*03-DQB1*02-DPB1*04 haplotype had higher lymphoproliferative responses to measles virus (P=.01) and mumps virus (P=.006). The DRB1*15/16-DQB1*06-DPB1*03 haplotype was associated with high levels of IgG antibody to measles virus (P=.09) but low levels of IgG antibody to rubella virus (P=.02), whereas DRB1*04-DQB1*03-DPB1*03 was associated with high lymphoproliferative responses to both measles (P=.01) and rubella (P=.002) vaccine viruses. A*26-Cw*12-B*38 was associated with both mumps virus-specific humoral (P=.007) and cell-mediated (P=.01) immune responses after 2 doses of MMR vaccine. Haplotype DRB1*04-DQB1*03-DPB1*03 was associated with both lower rubella virus IgG antibody levels (P=.02) and higher rubella virus-specific lymphoproliferation (P=.002). Better characterization of such HLA profiles could inform and improve the design of novel epitope-rich vaccines and help to predict protective immune responses at the individual and population level. To elucidate the contribution of human leukocyte antigen (HLA) haplotypes and their genotypic combinations to immune status after measles-mumps-rubella (MMR) vaccination, 346 children 12-18 years of age were studied. The class I A*29-Cw*16-B*44 haplotype was associated with lower levels of immunoglobulin G (IgG) antibody to both measles (P=.08) and mumps (P=.03) viral antigens. The A*26-Cw*12-B*38 haplotype was associated with higher cellular immune responses to measles (P=.02) and mumps (P=.01) vaccine viruses. Subjects with the class II DRB1*03-DQB1*02-DPB1*04 haplotype had higher lymphoproliferative responses to measles virus (P=.01) and mumps virus (P=.006). The DRB1*15/16-DQB1*06-DPB1*03 haplotype was associated with high levels of IgG antibody to measles virus (P=.09) but low levels of IgG antibody to rubella virus (P=.02), whereas DRB1*04-DQB1*03-DPB1*03 was associated with high lymphoproliferative responses to both measles (P=.01) and rubella (P=.002) vaccine viruses. A*26-Cw*12-B*38 was associated with both mumps virus-specific humoral (P=.007) and cell-mediated (P=.01) immune responses after 2 doses of MMR vaccine. Haplotype DRB1*04-DQB1*03-DPB1*03 was associated with both lower rubella virus IgG antibody levels (P=.02) and higher rubella virus-specific lymphoproliferation (P=.002). Better characterization of such HLA profiles could inform and improve the design of novel epitope-rich vaccines and help to predict protective immune responses at the individual and population level To elucidate the contribution of human leukocyte antigen (HLA) haplotypes and their genotypic combinations to immune status after measles-mumps-rubella (MMR) vaccination, 346 children 12-18 years of age were studied. The class I A*29-Cw*16-B*44 haplotype was associated with lower levels of immunoglobulin G (IgG) antibody to both measles (P = .08) and mumps (P = .03) viral antigens. The A*26-Cw* 12-B*38 haplotype was associated with higher cellular immune responses to measles (P = .02) and mumps (P — .01) vaccine viruses. Subjects with the class II DRB1*03-DQB1*02-DPB1*04 haplotype had higher lymphoproliferative responses to measles virus (P = .01) and mumps virus (P = .006). The DRB1*15Z16-DQB1*06-DPB1*03 haplotype was associated with high levels of IgG antibody to measles virus (P = .09) but low levels of IgG antibody to rubella virus (P = .02), whereas DRB1*04-DQB1*03-DPB1*03 was associated with high lymphoproliferative responses to both measles (P = .01) and rubella (P = .002) vaccine viruses. A*26-Cw*12-B*38 was associated with both mumps virus-specific humoral (P = .007) and cell-mediated (P = .01) immune responses after 2 doses of MMR vaccine. Haplotype DRB1 *04-DQB 1*03-DPB 1*03 was associated with both lower rubella virus IgG antibody levels (P = .02) and higher rubella virus-specific lymphoproliferation (P = .002). Better characterization of such HLA profiles could inform and improve the design of novel epitope-rich vaccines and help to predict protective immune responses at the individual and population level. To elucidate the contribution of human leukocyte antigen (HLA) haplotypes and their genotypic combinations to immune status after measles-mumps-rubella (MMR) vaccination, 346 children 12-18 years of age were studied. The class I A*29-Cw*16-B*44 haplotype was associated with lower levels of immunoglobulin G (IgG) antibody to both measles (P = .08) and mumps (P = .03) viral antigens. The A*26-Cw*12-B*38 haplotype was associated with higher cellular immune responses to measles (P = .02) and mumps (P= .01) vaccine viruses. Subjects with the class II DRB1*O3-DQB1*O2-DPB1*O4 haplotype had higher lymphoproliferative responses to measles virus (P = .01) and mumps virus (P = .006). The DRB1*15/16-DQB1*O6-DPB1*O3 haplotype was associated with high levels of IgG antibody to measles virus (P = .09) but low levels of IgG antibody to rubella virus (P = .02), whereas DRB1*O4-DQB1*O3-DPB1*O3 was associated with high lymphoproliferative responses to both measles (P = .01) and rubella (P = .002) vaccine viruses. A*26-Cw*12-B*38 was associated with both mumps virus-specific humoral (P = .007) and cell-mediated (P = .01) immune responses after 2 doses of MMR vaccine. Haplotype DRB1*O4-DQB1*O3-DPB1*O3 was associated with both lower rubella virus IgG antibody levels (P = .02) and higher rubella virus-specific lymphoproliferation (P = .002). Better characterization of such HLA profiles could inform and improve the design of novel epitope-rich vaccines and help to predict protective immune responses at the individual and population level. |
Author | Pankratz, V. Shane Vierkant, Robert A. Ovsyannikova, Inna G. Jacobson, Robert M. Poland, Gregory A. |
Author_xml | – sequence: 1 givenname: Inna G. surname: Ovsyannikova fullname: Ovsyannikova, Inna G. organization: Mayo Vaccine Research Group – sequence: 2 givenname: V. Shane surname: Pankratz fullname: Pankratz, V. Shane organization: Department of Health Sciences Research – sequence: 3 givenname: Robert A. surname: Vierkant fullname: Vierkant, Robert A. organization: Department of Health Sciences Research – sequence: 4 givenname: Robert M. surname: Jacobson fullname: Jacobson, Robert M. organization: Mayo Vaccine Research Group – sequence: 5 givenname: Gregory A. surname: Poland fullname: Poland, Gregory A. email: poland.gregory@mayo.edu organization: Mayo Vaccine Research Group |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17591499$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/16453260$$D View this record in MEDLINE/PubMed |
BookMark | eNqF0VGL1DAQB_AgJ97eqt9AiYI-WU2aNG0ez0VvD_YQ7lTEl5Bmp5q9NqlNAu63t6XrHhyIT_Mwv_zJzJyhE-cdIPSUkreUVOJdQQjl_AFa0IKVmRCUnaAFIXme0UrKU3QWwo4QwpkoH6FTKnjBckEWqFunTju8gXTrzT4CPnfR_gCH17pvfdz3ELB1OP4EfAEOojV45V0cfIt9gy-7LjnA1xB67wLg6PEV6NBCyK5S14fsOtXQthp_1cZYB4_Rw0a3AZ4c6hJ9-fjh82qdbT5dXK7ON5nhFYsZNHSraz6-MXyqVFJdmxoanXPgupBMa7qtCTeC1JRVpJAVg7IkjDaSVw1botdzbj_4XwlCVJ0NZvqJA5-CEqXIOSvEfyEtiaRsTF-il_fgzqfBjUOoPGdy3Cyf0p4fUKo72Kp-sJ0e9urvukfw6gB0MLptBu2MDXeuLCTlUo7uzezM4EMYoFHGRh3ttHltW0WJmq6u5qvfTXHkx8T78MUMfer_bZ7NZheiH46KkdHwqhz72dy3IcLvY18Pt-NaWVmo9bfvqqzEzfu1vFGC_QGo-8w9 |
CODEN | JIDIAQ |
CitedBy_id | crossref_primary_10_1126_scitranslmed_aab4005 crossref_primary_10_1016_j_vaccine_2008_06_057 crossref_primary_10_1208_s12248_011_9281_x crossref_primary_10_1186_1471_2172_11_48 crossref_primary_10_1016_j_vaccine_2011_05_068 crossref_primary_10_1371_journal_pone_0171261 crossref_primary_10_1016_j_vaccine_2012_12_026 crossref_primary_10_3389_fimmu_2020_01181 crossref_primary_10_1016_j_clim_2014_02_011 crossref_primary_10_1038_sj_clpt_6100415 crossref_primary_10_1016_j_cyto_2006_12_001 crossref_primary_10_1016_j_vaccine_2024_126527 crossref_primary_10_1089_omi_2011_0032 crossref_primary_10_1007_s13312_021_2165_y crossref_primary_10_1016_j_vaccine_2017_02_013 crossref_primary_10_1016_j_vaccine_2009_01_080 crossref_primary_10_1098_rstb_2014_0341 crossref_primary_10_1128_CMR_00048_08 crossref_primary_10_1016_j_vaccine_2009_08_109 crossref_primary_10_3389_fimmu_2022_1054147 crossref_primary_10_1016_j_jinf_2010_06_012 crossref_primary_10_1016_j_vaccine_2007_01_020 crossref_primary_10_1111_sji_13266 crossref_primary_10_2217_pgs_09_25 crossref_primary_10_1016_j_paed_2009_08_019 crossref_primary_10_1016_j_smim_2013_04_007 crossref_primary_10_1093_infdis_jir167 crossref_primary_10_1097_FPC_0b013e32834df186 crossref_primary_10_1007_s00439_008_0511_y crossref_primary_10_1016_j_vaccine_2011_08_058 crossref_primary_10_1080_21645515_2020_1849520 crossref_primary_10_1007_s00439_009_0720_z crossref_primary_10_1371_journal_pone_0011806 crossref_primary_10_1016_j_vaccine_2011_02_071 crossref_primary_10_1517_14712598_8_11_1659 crossref_primary_10_1016_j_vaccine_2013_09_026 crossref_primary_10_1128_CVI_05652_11 crossref_primary_10_1128_JVI_00883_10 crossref_primary_10_1093_infdis_jir065 crossref_primary_10_1016_j_coi_2011_04_005 crossref_primary_10_1016_j_molmed_2015_10_005 crossref_primary_10_1016_j_vaccine_2011_08_060 crossref_primary_10_1016_j_vaccine_2012_01_038 crossref_primary_10_1111_j_1399_0039_2007_00986_x crossref_primary_10_1371_journal_pone_0064813 crossref_primary_10_1371_journal_ppat_1002344 crossref_primary_10_1038_gene_2011_15 crossref_primary_10_1586_erv_12_134 crossref_primary_10_2174_0113816128280417231204085137 crossref_primary_10_1080_21645515_2019_1675458 crossref_primary_10_1038_s41467_021_22236_7 crossref_primary_10_1016_j_vaccine_2012_07_063 crossref_primary_10_1371_journal_pone_0062149 crossref_primary_10_1016_j_vaccine_2023_02_009 crossref_primary_10_1007_s00439_014_1449_x crossref_primary_10_1542_peds_2007_1575 crossref_primary_10_1016_j_humimm_2021_09_006 crossref_primary_10_1007_s00439_014_1471_z crossref_primary_10_1016_j_vaccine_2008_05_011 crossref_primary_10_1128_CMR_00084_18 crossref_primary_10_3390_v15040906 |
ContentType | Journal Article |
Copyright | Copyright 2006 Infectious Diseases Society of America 2006 by the Infectious Diseases Society of America 2006 2006 INIST-CNRS Copyright University of Chicago Press Mar 1, 2006 |
Copyright_xml | – notice: Copyright 2006 Infectious Diseases Society of America – notice: 2006 by the Infectious Diseases Society of America 2006 – notice: 2006 INIST-CNRS – notice: Copyright University of Chicago Press Mar 1, 2006 |
DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM K9. NAPCQ 7T5 7U9 8FD FR3 H94 P64 RC3 7X8 |
DOI | 10.1086/500144 |
DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Immunology Abstracts Virology and AIDS Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Genetics Abstracts Virology and AIDS Abstracts Technology Research Database AIDS and Cancer Research Abstracts Immunology Abstracts Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) MEDLINE MEDLINE - Academic Genetics Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Biology |
EISSN | 1537-6613 |
EndPage | 663 |
ExternalDocumentID | 995463221 16453260 17591499 10_1086_500144 10.1086/500144 30086487 ark_67375_HXZ_786SBH9S_6 |
Genre | Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NIAID NIH HHS grantid: AI 48793 – fundername: NCRR NIH HHS grantid: MO1 RR00585 – fundername: NIAID NIH HHS grantid: AI 33144 |
GroupedDBID | --- -DZ -~X ..I .2P .55 .GJ .I3 .XZ .ZR 08P 0R~ 123 1TH 29K 2AX 2WC 36B 4.4 48X 53G 5GY 5RE 5VS 5WD 70D 85S AABZA AACGO AACZT AAHBH AAHTB AAJKP AAJQQ AAMVS AANCE AAOGV AAPNW AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP AAWTL ABBHK ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABOCM ABPEJ ABPLY ABPPZ ABPQP ABPTD ABQLI ABQNK ABTLG ABVGC ABWST ABXSQ ABXVV ABZBJ ACGFO ACGFS ACGOD ACHIC ACPRK ACUFI ACUTO ACYHN ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADQXQ ADRTK ADULT ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEUPB AEWNT AEXZC AFFNX AFFZL AFIYH AFOFC AFXAL AFYAG AGINJ AGKEF AGORE AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AIAGR AIJHB AJBYB AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN AQVQM ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BR6 BSCLL BTRTY BVRKM C45 CDBKE CS3 CZ4 D-I DAKXR DCCCD DIK DILTD DU5 D~K EBS ECGQY EE~ EJD EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H5~ HAR HQ3 HTVGU HW0 HZ~ IH2 IOX IPSME J21 J5H JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JST JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B LSO LU7 MHKGH MJL ML0 MVM N4W N9A NEJ NGC NOMLY NOYVH NU- NVLIB O0~ O9- OAUYM OAWHX OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q1. Q5Y QBD RD5 ROX ROZ RUSNO RW1 RXO SA0 SJN TCURE TEORI TJX TR2 W2D W8F WH7 X7H X7M YAYTL YKOAZ YXANX ZGI ~91 AAYOK AASNB ADACV ADJQC ADRIX AFXEN DOOOF ESX JSODD M49 1KJ 3O- 41~ AAFWJ AAPGJ AAWDT AAYXX ABDPE ABSMQ ACFRR ACPQN ACUTJ ACVCV ACZBC ADMTO AEKPW AFFQV AFHKK AFQQW AFSHK AGKRT AGMDO AHGBF AI. AJDVS APJGH AQDSO AQKUS AVNTJ BZKNY CITATION EIHJH H13 MBLQV OBFPC O~Y P0- TMA VH1 Y6R ZE2 ZXP IQODW CGR CUY CVF ECM EIF NPM VXZ YIF K9. NAPCQ 7T5 7U9 8FD FR3 H94 P64 RC3 7X8 |
ID | FETCH-LOGICAL-c483t-ef1dab4accc4ab4a191abcbefa24e4a593aa1db04c60b13805983e77031f948f3 |
ISSN | 0022-1899 |
IngestDate | Fri Sep 05 00:40:30 EDT 2025 Fri Sep 05 10:47:17 EDT 2025 Fri Jul 25 19:25:27 EDT 2025 Wed Feb 19 01:43:37 EST 2025 Mon Jul 21 09:16:15 EDT 2025 Tue Jul 01 03:23:48 EDT 2025 Thu Apr 24 23:04:51 EDT 2025 Wed Sep 11 04:50:41 EDT 2024 Fri Jun 20 02:31:52 EDT 2025 Tue Aug 05 16:48:09 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | Infection Rubella HLA-System Immune response Microbiology Viral disease Measles Vaccine Mumps Genetic determinism Haplotype |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c483t-ef1dab4accc4ab4a191abcbefa24e4a593aa1db04c60b13805983e77031f948f3 |
Notes | istex:B1991BBA134AFCCAE4B7FA58906915B09427363B ark:/67375/HXZ-786SBH9S-6 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-General Information-1 content type line 14 ObjectType-Feature-3 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://academic.oup.com/jid/article-pdf/193/5/655/18010567/193-5-655.pdf |
PMID | 16453260 |
PQID | 223900446 |
PQPubID | 41591 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_67624356 proquest_miscellaneous_17091398 proquest_journals_223900446 pubmed_primary_16453260 pascalfrancis_primary_17591499 crossref_citationtrail_10_1086_500144 crossref_primary_10_1086_500144 oup_primary_10_1086_500144 jstor_primary_30086487 istex_primary_ark_67375_HXZ_786SBH9S_6 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2006-03-01 |
PublicationDateYYYYMMDD | 2006-03-01 |
PublicationDate_xml | – month: 03 year: 2006 text: 2006-03-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Chicago, IL |
PublicationPlace_xml | – name: Chicago, IL – name: United States – name: Oxford |
PublicationTitle | The Journal of infectious diseases |
PublicationTitleAbbrev | The Journal of Infectious Diseases |
PublicationTitleAlternate | The Journal of Infectious Diseases |
PublicationYear | 2006 |
Publisher | The University of Chicago Press University of Chicago Press Oxford University Press |
Publisher_xml | – name: The University of Chicago Press – name: University of Chicago Press – name: Oxford University Press |
SSID | ssj0004367 |
Score | 2.1358876 |
Snippet | To elucidate the contribution of human leukocyte antigen (HLA) haplotypes and their genotypic combinations to immune status after measles-mumps-rubella (MMR)... |
SourceID | proquest pubmed pascalfrancis crossref oup jstor istex |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 655 |
SubjectTerms | Adolescent Antibodies Antibodies, Viral - blood Applied microbiology Biological and medical sciences Child Fundamental and applied biological sciences. Psychology Haplotypes HLA antigens HLA Antigens - genetics HLA Antigens - immunology Human viral diseases Humans Immune response Immunity, Cellular Immunoglobulin G - blood Infectious diseases Lymphocyte Activation Lymphocytes - immunology Measels mumps rubella vaccine Measles Measles virus Measles virus - immunology Measles-Mumps-Rubella Vaccine - immunology Medical sciences Microbiology Mumps Mumps virus Mumps virus - immunology Rubella Rubella virus Statistics as Topic Vaccination Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Viral diseases Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye Viruses |
Title | Human Leukocyte Antigen Haplotypes in the Genetic Control of Immune Response to Measles-Mumps-Rubella Vaccine |
URI | https://api.istex.fr/ark:/67375/HXZ-786SBH9S-6/fulltext.pdf https://www.jstor.org/stable/30086487 https://www.ncbi.nlm.nih.gov/pubmed/16453260 https://www.proquest.com/docview/223900446 https://www.proquest.com/docview/17091398 https://www.proquest.com/docview/67624356 |
Volume | 193 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKJtAkhGAw1g2GH4CXKVPSOE7yCAioKhUedlHFS2QntoC2SdWkFeWd_83xJZexVQJe2ip2k7TfZ-ccn8_nIPQykoySjHJlubkOkZ7v8MAVjqSSZ4GQZKDF4-NPdHhJRpNg0uv96qiWVhU_S3_euq_kf1CFY4Cr2iX7D8g2J4UD8BnwhVdAGF7_CmOzAj8Tq2mRbioVCKhUcs3Tr2wxK9TialnLGOGo2q3YKNNVogi1M0QVTdEiWV1BYy5YORPg_ALGpbNcqaAEO12ztIm-f2_JNermnDCKrlVZB3waS_3zutyoskjTYs3MfJSzTj0vlk-BgnoR-0olj26D_FfwvJ4ykxXByL_bZdcRTON13XPbNv5z-aLWb3W2E3iRqZLUTMmmaqLlXtCZYKlJ6ntj4nd1HCpQHh_pdgDAFnMNP_iFAdiqbvvga-SIddMdtDsIQx3t_zhplULEp2GddF7daadElbmgyjxrT3HNvNlVI_VHrXStt1DeX7ASxp80hVO2ezbawrl4iB5YPPEbw7NHqCfyfXTXFCvd7KN7YyvDeIzmmni4IR62xMMt8fC3HAPxsCUetsTDhcSGeLgmHq4KfCvxsCXeE3T54f3Fu6Fj63Y4KYn8yhHSyxgn0Ccl6t2LPcZTLiQbEEFYEPuMeRl3SUpd7vkRWPiRL0JVSUHGJJL-AdrJi1wcIuxLmXEwicExyIifykj70wMifY-F4Az30av6705Sm9Re1VaZJVpcEdHEINRHL5p-C5PG5UaP1xqtppktp0r0GAbJcPIlCSN6_nYYnye0jw40nE1HXy0LgN_fR0eA79bTn1yDve0WBrFHYvglxzUPEjvFlAnY7rGWXMD9N60w_6ugHoxIGNbwfZ3ZN9reg4K9A04RnOOpoVd7bUvao60tx2ivHbTP0E61XInnYIVX_ESPkd8Lgd0D |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Human+leukocyte+antigen+haplotypes+in+the+genetic+control+of+immune+response+to+measles-mumps-rubella+vaccine&rft.jtitle=The+Journal+of+infectious+diseases&rft.au=Ovsyannikova%2C+Inna+G&rft.au=Pankratz%2C+V+Shane&rft.au=Vierkant%2C+Robert+A&rft.au=Jacobson%2C+Robert+M&rft.date=2006-03-01&rft.issn=0022-1899&rft.volume=193&rft.issue=5&rft.spage=655&rft_id=info:doi/10.1086%2F500144&rft_id=info%3Apmid%2F16453260&rft.externalDocID=16453260 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1899&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1899&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1899&client=summon |